Novavax (NVAX) Stock Looks Like A Bargain On Sales But Fully Priced Overall

Novavax stock has delivered a steep 96.1% decline over the past five years, and the current valuation checks and market multiples now point to a more mixed picture rather than a clear bargain or clear overvaluation.

• The share price has fallen 96.1% over five years, which puts extra focus on whether the current market value still reflects the risks around the business.
• Expectations for future revenue and cash flow can support the current valuation, while uncertainty around execution and funding needs may limit how much investors are willing to pay for Novavax.
• The broader checks suggest a mixed picture, with Novavax passing 4 out of 6 valuation tests, which you can review in more detail here.

The issue now is whether the current market price of Novavax fairly reflects this balance of past losses, current risks and the mixed valuation signals.

Find out why Novavax's 11.6% return over the last year is lagging behind its peers.

Does Novavax Look Pricey on Sales?

P/S is often useful for a business like Novavax because revenue is a cleaner yardstick when earnings and cash flows are still volatile. On this measure, Novavax trades on a P/S ratio of 2.0x, which is well below the wider biotech industry average of 10.5x and the peer group average of 43.2x.

The fair P/S ratio implied by the model is 1.5x. That is lower than where Novavax stock currently trades, even though the industry and peer benchmarks are higher. On this framework, investors are paying more than the model suggests is reasonable once factors such as margins, risk profile and size are taken into account, despite the apparent discount to the sector averages.

Overall, the stock screens as overvalued on the P/S multiple relative to the modelled fair ratio, even though its headline sales multiple sits well below typical biotech levels.

See what the numbers say about this price — find out in our valuation breakdown.

The Novavax Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Novavax pick up where the valuation puzzle leaves off and explain which combinations of future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price. Each one sets out a fair value as a thesis about Novavax's business that you can track over time. This allows you to see how well it holds up as new information comes through on the Community page.

The community view on Novavax sits on a wide spectrum, with one side leaning into licensing and royalties while the other questions how durable that opportunity really is.

Bull case: 47% undervalued

"Partnership with Sanofi has de-risked commercial execution for Nuvaxovid and opened doors for future milestone and royalty streams, particularly as Sanofi develops and commercializes COVID-influenza combination vaccines, which could meaningfully boost Novavax's recurring revenue and net margins…"

Read the full Bull Case to see why Novavax could be undervalued

Bear case: roughly fairly valued

"Heavy historical dependence on a narrow product portfolio, primarily COVID-19 and flu vaccines, magnifies Novavax's vulnerability to rapid market saturation, declining demand post-pandemic, and competitive displacement, increasing the likelihood of sharp revenue contraction once near-term milestone payments and royalties subside…"

Read the full Bear Case to see why Novavax could be overvalued

Do you think there's more to the story for Novavax? Head over to our Community to see what others are saying!

The Bottom Line

For now, Novavax screens as overvalued on the key market multiple being used, even though its headline P/S ratio looks low against biotech peers. The mixed broader checks suggest investors are already factoring in a fair amount of execution and funding risk. This helps explain why the apparent discount to the sector is not a clear green light. The crux from here is whether Novavax can turn its partnerships and product portfolio into durable, higher quality revenue that justifies the current multiple instead of leaving the stock as a potential value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com